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Abstract
Background: The differential diagnosis of metastatic mammary adenocarcinoma and
adenocarcinomas from other primary sites can be challenging, particularly in tumors that are poorly
differentiated and negative for Estrogen/Progesterone receptors (ER/PR). With progression of
disease, Androgen receptors (AR) are preserved with higher frequency than ER/PR in metastatic
mammary carcinoma. This study was undertaken to evaluate the diagnostic significance of AR
expression in adenocarcinoma of breast and other morphologically similar adenocarcinomas.
Design: Formalin-fixed paraffin-embedded tissue sections of 113 primary adenocarcinoma of
various sites [breast (34, all females), lung (23, M- 6, F-17), colon (9, M-2, F-7), stomach (6, M-4, F-
2), liver and bile duct (11, M-5, F-6), pancreas (7, M-2, F-5), ovary (10), endometrium (7), and cervix
(6)] were immunostained with monoclonal antibody for AR. Except for well differentiated lobular
carcinoma of breast (5) and bronchoalveolar carcinoma of lung (10), majority of the tumors were
moderately to poorly differentiated. Tumors immunoreactive for ≥ 10% of nuclei were considered
AR positive. However, AR immunoreactivity in the cytoplasm only was also recorded.
Results: 56% (19/34) mammary carcinoma and 20% (2/10) adenocarcinoma of ovary were positive
for AR. Remaining 69 adenocarcinomas did not show nuclear immunoreactivity for AR in ≥ 10%
nuclei; however, 52% (36/69) showed variable cytoplasmic immunoreactivity.
Conclusion: Significant proportion of mammary carcinomas and some ovarian carcinomas
express AR in the nuclei of more than 10% tumor cells. If metastatic tumor with unknown primary
in a female is AR positive, breast and ovary are the most likely primary sites. Cytoplasmic
immunoreactivity alone without nuclear immunoreactivity for AR was non-specific for this
differential diagnosis.
Background
Over the years with vast advances in the chemotherapeu-
tic regimes specific for certain primary sites of tumors, the
correct identification of the origin of tumor is of utmost
importance for the determination of appropriate therapy
and prognosis. In women, mammary carcinoma is a lead-
ing cause of death in several regions of the world [1]. It is
an important differential in the evaluation of metastatic
tumor especially in locations like axillary lymph nodes,
lung, liver, and body fluids where it is one of the most
common metastatic tumors in women [2].
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ocarcinoma may not always be discernible by morphol-
ogy alone. Immunohistochemistry has proved to be a
useful adjunct for this purpose. Commonly applied pan-
els of immunomarkers for breast carcinoma including ER,
PR, GCDFP-15 (Gross Cystic Disease Fluid Protein-15),
and lactoferrin while very useful [3-6] may be inconclu-
sive [7,8].
Previous studies have shown that AR is retained more
often than ER/PR in metastatic mammary carcinoma
[9,10], being the sole receptor in 25% of metastatic breast
tumors in a report [9]. AR expression in primary breast
cancer has been observed in 34–100% of cases in several
reports [9,11-14]. The higher frequency of AR expression
as compared to ER/PR makes it a promising addition to a
panel of immunohistochemical markers for assessment of
metastatic carcinomas. However, the status of AR by
immunohistochemistry in other poorly differentiated car-
cinomas that may enter in the differential diagnosis for
mammary carcinoma has not been evaluated previously.
This study was undertaken to examine the expression of
AR by immunohistochemistry in poorly differentiated pri-
mary breast carcinoma and adenocarcinomas from vari-
ous other sites.
The tumors that are included in our study are primary ade-
nocarcinomas from breast, lung, stomach, pancreas, liver
(cholangiocarcinoma), colon, ovary, endometrium, and
cervix.
Materials and methods
A total of 113 cases were obtained after a computerized
search from Anatomic Pathology files at Froedtert Hospi-
tal/Medical College of Wisconsin from 1996 to 2001. The
neoplasms studied included the following: 34 mammary
carcinomas (29 ductal, 5 lobular), 10 ovarian carcinomas,
7 uterine endometrial carcinomas, 6 uterine cervix adeno-
carcinomas, 11 liver and bile duct cholangiocarcinomas
(M-5, F-6), 7 pancreatic adenocarcinomas (M-2, F-5), 6
gastric carcinomas (M-4, F-2), 9 colon carcinomas (M-2,
F-7), and 23 adenocarcinomas of the lung (M-6, F-17)
including 10 of the broncho-alveolar type. Majority of the
tumors except for lobular carcinoma of the breast and
broncho-alveolar carcinoma of the lung were of a moder-
ately to poorly differentiated grade. All of these tumors
were primary tumors of their respective organs. Out of the
56 adenocarcinomas (other than mammary carcinoma,
ovarian carcinoma, uterine endometrial and cervical carci-
nomas of the female gender), 19 tumors belonged to
males and 37 to females.
These specimens were fixed in 10% formalin and embed-
ded in paraffin blocks. Sections of 3.5 micron in thickness
were cut and mounted on DAKO silanized slides to
accommodate alkaline epitope retrieval. They were then
dried and depariffinized. The endogenous peroxidase
activity was blocked using 50/50 methanol/H2O2 solution
following which antigen retrieval is performed with
DAKO pH 10.0 citrate buffer at 95°C for 20 minutes. After
allowing it to cool down, non-specific binding was
quashed with DAKO protein block. The tissue was then
immunostained for 45 minutes with monoclonal
antibodyAR441 (Dako, Carpinteria, CA) corresponding
to amino acids 229–315 of the human androgen receptor
at a dilution of 1:100. The signal was visualized with
DAKO LSAB+. Then they were placed in DAKO DAB+ for
7 minutes. Lastly hematoxylin counter stain was per-
formed using Harris Hematoxylin. Tumors were consid-
ered positive for AR if 10% or greater than 10% of nuclei
were immunoreactive. Cytoplasmic reactivity alone with
AR was interpreted as negative, but was recorded for ana-
lyzing the results. Formalin fixed paraffin-embedded tis-
sue sections of prostate served as a positive control.
Results
Of the 34 breast carcinoma cases, 29 were of infiltrating
ductal type (IDC) and 5 of infiltrating lobular type (ILC).
All of the IDC were assigned Bloom and Richardson grade
3. Nuclear immunoreactivity was observed in 56% (19/
34) of the total breast cases. Out of the 29 cases of IDC, 14
were positive for AR. All 5 ILC were positive for AR. The
staining pattern for AR was patchy in many of the tumors
with proportion of tumor nuclei exhibiting immunoposi-
tivity for AR varying from 40–100%. The intensity also
varied from weak to strong. In the ILC group, 4 cases dis-
played positive nuclear immunostaining with strong
intensity, and in 1 case 75% of the nuclei stained positive
with moderate to strong intensity. Simultaneous or iso-
lated cytoplasmic staining with AR, ranging from weak to
strong was noted in 62% (21/34) of these breast carcino-
mas.
The group of 10 ovarian tumors included 5 papillary
serous adenocarcinomas, 3 endometriod carcinomas, 1
mixed papillary mucinous and serous adenocarcinoma,
and 1 mixed endometriod – papillary serous adenocarci-
noma. Immunoreactivity with AR was noted in 2 of these
tumors, a papillary serous adenocarcinoma and the other
mixed endometriod – papillary serous adenocarcinoma.
Moderate to strong staining was noted in 80% and 95% of
the tumor nuclei in these 2 tumors respectively. Nine out
of the ten ovarian tumors displayed variable cytoplasmic
immunoreactivity with AR.
Out of the 10 cases selected initially as colon adenocarci-
noma, one tumor displayed AR immunoreactivity in scat-
tered malignant glands but was negative in the poorly
differentiated regions of the tumor. This tumor belonged
to a male patient. Due to morphology unusual for colonPage 2 of 6
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antigen (PSA) immunomarker was performed to deter-
mine if this tumor had possible prostate origin. PSA
immunoreactivity was observed in areas showing few
well-differentiated malignant glands consistent with pro-
static adenocarcinoma. The tumor was predominantly
poorly differentiated and these poorly differentiated cells
did not show AR immunoreactivity. Patient had a past his-
tory of prostatic adenocarcinoma. The rest of the colon
adenocarcinoma cases showed non-reactivity of the nuclei
with AR although variable cytoplasmic staining was noted
in 7 of the 9 cases.
Amongst the 7 cases initially selected as gastric carcinoma,
six did not display nuclear immunoreactivity for AR; how-
ever, one case belonging to a female patient showed mod-
erate to strong positive nuclear staining with AR in 60% of
the nuclei. Further immunohistochemical studies were
performed which demonstrated immunoreactivity of the
tumor cells for ER (20–30% nuclei with moderate inten-
sity), PR (90% nuclei with strong intensity) and Cytoker-
atin 7. These tumor cells were negative for Cytokeratin 20,
consistent with metastatic mammary carcinoma. Patient
had a past history of mammary carcinoma. Cytoplasmic
staining was noted in 3 out of the 6 gastric carcinoma
cases.
Remaining 54 adenocarcinomas, including pancreatic
adenocarcinomas (7), liver and bile duct cholangiocarci-
nomas (11), uterine endometrial carcinomas (7), uterine
cervix adenocarcinomas (6), and pulmonary adenocarci-
nomas including broncho-alveolar type (23), did not
show nuclear immunonegativity for AR. However 48%
(26/54) of these tumors demonstrated variable cytoplas-
mic reactivity. Out of all 69 non-mammary/non-ovarian
adenocarcinomas, 52% (36/69) showed variable cyto-
plasmic immunoreactivity.
Discussion
Androgen receptors are nuclear proteins that are function-
ally critical to several organs and tissues [15]. They are
expressed at variable levels in a number of tissues [16].
Intense staining has been reported in glandular epithelia
of male accessory organs (including prostrate, seminal
vesicles and epididymis), breast, and sebaceous and sweat
glands of skin [17,18]. In the testes, sertoli cells, peritubu-
lar myoid cells and interstitial cells were immunoreactive
with AR [17,18]. Stratified squamous epithelia of vagina
and cervix showed selective immunostaining of the basal
layer whereas in the preputial epithelia, the intensity of
immunoreactivity decreased gradually with maturation
[17].
AR expression has been noted in some benign and malig-
nant tumors. As noted earlier, majority of breast carcino-
mas evaluated express AR as determined by IHC and
biochemical studies [9,11-14]. In adenocarcinoma of the
prostate, AR has been demonstrated by IHC with consid-
erable heterogeneity in staining [18-21]. A significant
number of ovarian carcinomas are also positive for AR
[22,23]. Malignant cells in some endometrial adenocarci-
nomas were found to be immunoreactive [24]. AR has
also been detected by IHC in 90% of salivary duct carcino-
mas [25,26]. Amongst the benign tumors, AR expression
has been demonstrated in nasopharyngeal angiofibromas
[27], hepatic adenomas [28], and meningiomas [29].
Mammary carcinoma- Positive for Androgen receptors (≥ 10% nuclei are immunoreactive, 100×)Figure 1
Mammary carcinoma- Positive for Androgen receptors (≥ 10% nuclei are immunoreactive, 100×).Page 3 of 6
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to clinical and prognostic significance in estrogen recep-
tor-negative breast cancers [30].
In our study there was a clear dominance of AR expression
in mammary carcinoma compared to other adenocarcino-
mas. AR expression in 56% (19/34) of the mammary car-
cinomas is in concordance with previous studies. Whilst
48% (14/29) of the IDC's were immunoreactive for AR,
ILC cases demonstrated consistent AR positivity at 100%.
The higher frequency could be attributed to lower grade of
the ILC's as compared to the poorly differentiated IDC's
chosen in our study. It is noteworthy that 20% of ovarian
carcinomas were positive with immunoreactivity for AR in
more than 10% nuclei.
As specifically evaluated in this study, the nuclear immu-
nostaining pattern is important during interpretation.
Only nuclear immunostaining pattern was observed in
mammary carcinoma and in a few cases of ovarian carci-
noma. All other adenocarcinomas are negative for nuclear
immunoreactivity. However, cytoplasmic immunoreac-
tivity was not uncommon in many of these non-mam-
mary/non-ovarian carcinomas.
Two cases (1 female and 1 male) showed positive immu-
noreactivity for AR in nuclei in the tumors initially
selected in the non-mammary adenocarcinoma group.
After further evaluation with additional immunomarkers
and clinical correlation, these tumors were consistent with
metastatic adenocarcinomas. The primary sites respec-
tively were breast in a female and prostate in a male.
Positive for Androgen receptorsFigure 3
Positive for Androgen receptors. A. Infiltrating ductal carcinoma, B. Infiltrating lobular carcinoma, C. Ovarian carcinoma 
(40×).
A B C
Pancreatic carcinoma- Negative for Androgen receptors (None to <10% nuclei are immunoreactive, 100×)Figu  2
Pancreatic carcinoma- Negative for Androgen receptors (None to <10% nuclei are immunoreactive, 100×).Page 4 of 6
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chemical evaluation of unknown primary in women is
strongly recommended. Silanized slides are recom-
mended to avoid floating and washing away of the tissue
sections during alkaline epitope retrieval step. Depending
on the clinical correlation, including the status of ovaries
and breast, AR positivity favors primary from mammary
carcinoma and sometimes ovarian carcinoma.
In summary, AR immunoreactivity in 10% or more nuclei
is consistent with AR positive tumor, which is strongly
suggestive of breast and in some cases ovarian primary.
This study suggests that AR is a potentially useful immu-
nomarker in evaluating metastatic adenocarcinoma of
unknown primary in females. It is important to assess the
true nuclear immunoreactivity in tumor cells. Cytoplas-
mic immunostaining alone is non-specific for differential
diagnosis of these primary sites.
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Table 1: AR positivity in different tumors
Tumor Total (M+F) AR Positive Nuclear or Nuclear-Cytoplasmic immunoreactivity %(n) Cytoplasmic immunoreactivity
IDC 29 (All F) 48% (14/29) 55%(16/29)
ILC 5 (All F) 100% (5/5) 100% (5/5)
Ovary 10* 20% (2/10) 90% (9/10)
Endometrium 7 0% (0/7) 43%(3/7)
Cervix 6 0% (0/7) 17%(1/6)
Lung 23 (6 + 17)** 0% (0/23) 74%(17/23)
Colon 9 (2+7)*** 0% (0/9) 78%(7/9)
Stomach 6 (4+2)**** 0% (0/6) 50%(3/6)
Pancreas 7 (2+5) 0% (0/7) 43%(3/7)
Hepatobiliary 11 (5+6) 0% (0/11) 18%(2/11)
*Included 5 papillary serous adenocarcinomas, 3 endometrioid carcinomas, 1 mixed papillary mucinous and serous adenocarcinoma, and 1 mixed 
endometrioid and papillary serous adenocarcinoma.
** Included 13 poorly differentiated adenocarcinomas of lung and 10 bronchoalveolar carcinomas.
*** Initially 10 cases of colon adenocarcinoma were selected but one was excluded after concluding it to be metastatic prostrate adenocarcinoma 
to colon.
**** Initially 7 cases of gastric carcinoma were selected but one was later excluded following conclusion of it being metastatic mammary carcinoma 
to stomach.
Negative for Androgen receptors (40×)Figure 4
Negative for Androgen receptors (40×). A. Lung carcinoma (Nuclei- non-immunoreactive, Cytoplasm- immunoreactive), B. 
Endometrial carcinoma (Both, nuclei and cytoplasm- non-immunoreactive), C. Pancreatic carcinoma (Both, nuclei and cyto-
plasm- non-immunoreactive).
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